AI Science Tracker
EN

Cancer Center

1 discovery from 2024

Discoveries

A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.

Source check: Source checked. Not independent scientific confirmation.

Finding: The source's Methods/Results confirm the case-specific finding: The breast-cancer response model is tested across three external cohorts and a prospective cohort, with pathology-defined response and reported comparison to radiologists.

Technology: AI model for pathology-defined axillary response after neoadjuvant chemotherapy

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

AI contribution
Predicts pathology-defined axillary response after neoadjuvant chemotherapy and is evaluated on external and prospective cohorts.
Test and result
The source describes the cohort, reference or experimental comparison used for this result; the judgment is limited to that study design.
Limitation / still unknown
The reported evaluation does not establish prospective benefit or performance beyond the studied setting.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.1038/s41416-024-02726-3

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.